COST-EFFECTIVENESS OF ABATACEPT FOR THE TREATMENT OF PATIENTS WITH RHEUMATOID ARTHRITIS AFTER AN INADEQUATE RESPONSE TO METHOTREXATE IN CHILE

被引：0
|
作者：
Elgart, J. F. [1 ]
Gonzalez, L. [1 ]
Aiello, E. C. [2 ]
机构：
[1] UNLP CONICET La Plata, Ctr Colaborador OPS OMS, CENEXA Ctr Endocrinol Expt & Aplicada, La Plata, Buenos Aires, Argentina
[2] Bristol Myers Squibb, Buenos Aires, DF, Argentina
来源：
VALUE IN HEALTH | 2013年 / 16卷 / 03期
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
引用
收藏
页码：A223 / A223
页数：1
相关论文
共 50 条
  • [21] Safety and Efficacy of Abatacept Over 4 Years of Treatment in Patients with Rheumatoid Arthritis and an Inadequate Response to Methotrexate in the AIM Trial
    Russell, A. S.
    Kremer, J. M.
    Emery, P.
    Abud-Mendoza, C.
    Szechinski, J.
    Zhao, C.
    Becker, J-C
    Westhovens, R.
    JOURNAL OF RHEUMATOLOGY, 2009, 36 (11) : 2608 - 2609
  • [22] Cost-Effectiveness of Early Treatment with Originator Biologics or Their Biosimilars After Methotrexate Failure in Patients with Established Rheumatoid Arthritis
    Dipen Patel
    Ahmed Shelbaya
    Raymond Cheung
    Jyoti Aggarwal
    Sang Hee Park
    Javier Coindreau
    Advances in Therapy, 2019, 36 : 2086 - 2095
  • [23] Abatacept improves both the physical and mental health of patients with rheumatoid arthritis who have inadequate response to methotrexate treatment
    Russell, A. S.
    Wallenstein, G. V.
    Li, T.
    Martin, M. C.
    Maclean, R.
    Blaisdell, B.
    Gajria, K.
    Cole, J. C.
    Becker, J-C
    Emery, P.
    ANNALS OF THE RHEUMATIC DISEASES, 2007, 66 (02) : 189 - 194
  • [24] Cost-Effectiveness of Early Treatment with Originator Biologics or Their Biosimilars After Methotrexate Failure in Patients with Established Rheumatoid Arthritis
    Patel, Dipen
    Shelbaya, Ahmed
    Cheung, Raymond
    Aggarwal, Jyoti
    Park, Sang Hee
    Coindreau, Javier
    ADVANCES IN THERAPY, 2019, 36 (08) : 2086 - 2095
  • [25] Cost-effectiveness of abatacept in patients with active rheumatoid arthritis (RA) and inadequate response to methotrexate (MTX) or tumor necrosis factor-alpha inhibitors (anti-TNFs): A Canadian perspective
    Maier-Moldovan, M.
    Yuan, Y.
    Maclean, R.
    L'Italien, G. J.
    VALUE IN HEALTH, 2008, 11 (03) : A257 - A257
  • [26] COST-EFFECTIVENESS OF TOCILIZUMAB FOR THE TREATMENT OF ACTIVE RHEUMATOID ARTHRITIS (RA) PATIENTS WITH INADEQUATE RESPONSE TO ANTI-TNF TREATMENT IN TURKEY
    Ertenli, I
    VALUE IN HEALTH, 2012, 15 (07) : A445 - A445
  • [27] A cost-effectiveness analysis of treatment options for patients with methotrexate-resistant rheumatoid arthritis in korea
    Sung, YK
    Choi, CB
    Park, EJ
    Kim, JJ
    Park, SJ
    Lee, EK
    Bae, SC
    ARTHRITIS AND RHEUMATISM, 2005, 52 (09): : S236 - S236
  • [28] A cost-effectiveness analysis of treatment options for patients with methotrexate (MTX)-naive rheumatoid arthritis.
    Choi, HK
    Seeger, JD
    Kuntz, KM
    ARTHRITIS AND RHEUMATISM, 2000, 43 (09): : S389 - S389
  • [29] COST-EFFECTIVENESS OF ABATACEPT FOR THE TREATMENT OF RHEUMATOID ARTHRITIS (RA) AFTER THE FAILURE OF A FIRST TNF INHIBITOR IN THE UNITED KINGDOM
    Pericleous, L.
    Lebmeier, M.
    VALUE IN HEALTH, 2011, 14 (07) : A307 - A308
  • [30] COST-EFFECTIVENESS ANALYSIS OF SUBCUTANEOUS TOCILIZUMAB PLUS METHOTREXATE IN RHEUMATOID ARTHRITIS TREATMENT
    Oksuz, E.
    Malhan, S.
    Yanik, L.
    Koc, E.
    Erdogan-Ciftci, E.
    Celik, H.
    Orfanos, P.
    VALUE IN HEALTH, 2018, 21 : S295 - S295
12345